Heart and skeletal muscle insulin resistance and abnormal myocardial flow reserve (MFR) occurs in patients with type-II diabetes. Improvement of heart and skeletal muscle insulin resistance with rosiglitazone use over...Heart and skeletal muscle insulin resistance and abnormal myocardial flow reserve (MFR) occurs in patients with type-II diabetes. Improvement of heart and skeletal muscle insulin resistance with rosiglitazone use over 16 weeks have been reported. However, it is not clear whether chronic use of troglitazone can improve heart and skeletal muscle insulin resistance and MFR. Materials and Methods: To test the hypothesis whether effects of troglitazone on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes, rest and dipyridamole stress perfusion positron emission tomography (PET) with 13N-ammonia and heart and skeletal muscle 18FDG PET scans under insulin clamping were undertaken before and 12 month after the initiation of troglitazone therapy (400 mg/day) in 23 patients with type-II diabetes. Twenty patients with type-II diabetes without CAD and without medications were served as controls. In controls, any medications were not added from the first PET study and 12 months after the second PET study. Results: Baseline myocardial blood flow (MBF) was comparable before and after the troglitazone group as was the controls. MBF during dipyridamole administration (0.56 mg/min/kg) was not significantly improved in troglitazone group and controls. MFR was not improved in troglitazone group and controls. In troglitazone group, whole body glucose disposal rate (GDR;μmole/min/kg) significantly improved (pre;19.0 ± 9.55, post;28.7 ± 15.3, p as did the skeletal muscle glucose utilization rate (SMGU (μmole/min/kg);pre;20.3 ± 12.0, post;34.8 ± 10.6, p insulin resistance is implicated in patients with type-II diabetes and impaired MFR is uncoupled with insulin resistance in the whole body and heart and skeletal muscle in patients with type-II diabetes.展开更多
目的分析冠心病患者糖脂代谢水平与心肌缺血程度的相关性。方法选取2018年12月至2020年12月九江市第一人民医院确诊的60例冠心病患者作为研究对象,根据血流储备分数(FFR)测量结果分为心肌缺血组(FFR<0.80,n=33)和无心肌缺血组(FFR≥0...目的分析冠心病患者糖脂代谢水平与心肌缺血程度的相关性。方法选取2018年12月至2020年12月九江市第一人民医院确诊的60例冠心病患者作为研究对象,根据血流储备分数(FFR)测量结果分为心肌缺血组(FFR<0.80,n=33)和无心肌缺血组(FFR≥0.80,n=27),两组均进行糖脂代谢水平检测,比较两组糖脂代谢水平,分析糖脂代谢水平与FFR的相关性。结果心肌缺血组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbAlc)水平均高于无心肌缺血组,差异有统计学意义(P<0.05);心肌缺血组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均明显高于无心肌缺血组,而高密度脂蛋白胆固醇(HDL-C)水平明显低于无心肌缺血组,差异有统计学意义(P<0.05);FPG、2hPG、HbAlc、TC、TG、LDL-G、HDL-C水平与FFR均呈负相关(P<0.05)。结论冠心病患者的糖脂代谢水平与FFR呈现一定的负相关,可用于评估冠心病的心肌缺血程度。展开更多
文摘Heart and skeletal muscle insulin resistance and abnormal myocardial flow reserve (MFR) occurs in patients with type-II diabetes. Improvement of heart and skeletal muscle insulin resistance with rosiglitazone use over 16 weeks have been reported. However, it is not clear whether chronic use of troglitazone can improve heart and skeletal muscle insulin resistance and MFR. Materials and Methods: To test the hypothesis whether effects of troglitazone on heart and skeletal muscle insulin resistance and MFR in patients with type-II diabetes, rest and dipyridamole stress perfusion positron emission tomography (PET) with 13N-ammonia and heart and skeletal muscle 18FDG PET scans under insulin clamping were undertaken before and 12 month after the initiation of troglitazone therapy (400 mg/day) in 23 patients with type-II diabetes. Twenty patients with type-II diabetes without CAD and without medications were served as controls. In controls, any medications were not added from the first PET study and 12 months after the second PET study. Results: Baseline myocardial blood flow (MBF) was comparable before and after the troglitazone group as was the controls. MBF during dipyridamole administration (0.56 mg/min/kg) was not significantly improved in troglitazone group and controls. MFR was not improved in troglitazone group and controls. In troglitazone group, whole body glucose disposal rate (GDR;μmole/min/kg) significantly improved (pre;19.0 ± 9.55, post;28.7 ± 15.3, p as did the skeletal muscle glucose utilization rate (SMGU (μmole/min/kg);pre;20.3 ± 12.0, post;34.8 ± 10.6, p insulin resistance is implicated in patients with type-II diabetes and impaired MFR is uncoupled with insulin resistance in the whole body and heart and skeletal muscle in patients with type-II diabetes.
文摘目的分析冠心病患者糖脂代谢水平与心肌缺血程度的相关性。方法选取2018年12月至2020年12月九江市第一人民医院确诊的60例冠心病患者作为研究对象,根据血流储备分数(FFR)测量结果分为心肌缺血组(FFR<0.80,n=33)和无心肌缺血组(FFR≥0.80,n=27),两组均进行糖脂代谢水平检测,比较两组糖脂代谢水平,分析糖脂代谢水平与FFR的相关性。结果心肌缺血组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbAlc)水平均高于无心肌缺血组,差异有统计学意义(P<0.05);心肌缺血组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均明显高于无心肌缺血组,而高密度脂蛋白胆固醇(HDL-C)水平明显低于无心肌缺血组,差异有统计学意义(P<0.05);FPG、2hPG、HbAlc、TC、TG、LDL-G、HDL-C水平与FFR均呈负相关(P<0.05)。结论冠心病患者的糖脂代谢水平与FFR呈现一定的负相关,可用于评估冠心病的心肌缺血程度。
